KRAS and colorectal carcinoma: The combined treatment of β-elemene (125 g/mL) and cetuximab (25 g/mL) in KRAS mutant CRC cells HCT116 and Lovo showed a significant reduction in the activity of CRC cells, cell cycle arrest in the G0/G1 phase, and anti-proliferative effects.